« Return to News | R&D Trends

AbbVie, Alvine collaborate on investigational oral therapy

Monday, June 10, 2013 11:28 AM

AbbVie and Alvine Pharmaceuticals, a developer of celiac disease therapeutics, have entered a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in phase II development.

This collaboration builds on AbbVie's experience in gastroenterology with its on-market products to treat Crohn's disease, ulcerative colitis and diseases associated with exocrine pancreatic insufficiency.

"Celiac disease is an area with significant unmet medical need," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie. "Patients who currently are unable to completely avoid gluten in their diets could potentially benefit from this promising investigational treatment.”

 AbbVie will make an initial upfront payment of $70 million for an exclusive option to either acquire the assets relating to ALV003 or the equity of the company. Alvine will maintain responsibility for phase II clinical development, and upon successful completion of the approximately 500-patient phase IIb study, AbbVie may exercise its option. Alvine also will be entitled to receive a milestone payment upon AbbVie's initiation of phase III development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.